- Home
- » Tags
- » Abemaciclib
Top View
- Injectable and Health Care Administered Oncology Medical Drug Criteria Through Preferred (Optional)
- FDA-Approved Drugs Under Investigation in Multiple Myeloma for Actionable Targets
- 5.01.540 Miscellaneous Oncology Drugs
- Statistical Analysis Plan Version 1
- Verzenios, INN-Abemaciclib
- Appendix B - Product Name Sorted by Applicant
- January 2021 Forward-Looking Statements and Disclaimer
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Identification of Synergistic Drug Combinations Using Breast Cancer
- An Overview of the Recently Approved Small-Molecules Anticancer Drugs in the Past Decade
- The Top 15 Best-Selling Cancer Drugs in 2022 by Phil Taylor
- August 2021 Forward-Looking Statements and Disclaimer
- Focus on Triple-Negative Breast Cancer: Potassium Channel Expression and Clinical Correlates
- Self-Administered Specialty Drug List
- Stromal Senescence by Prolonged CDK4/6 Inhibition Potentiates Tumor Growth Xiangnan Guan1, Kyle M
- Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
- Abemaciclib, a Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
- Adjuvant Abemaciclib‑Induced Pneumonitis: a Case Report and Review of the Literature
- Abemaciclib (Verzenio), Palbociclib (Ibrance), and Ribociclib (Kisqali) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO050
- Protocol I3Y-MC-JPBO(D) a Phase 2 Study of Abemaciclib in Patients
- Protocol I3Y-MC-JPBL (C) MONARCH 2
- Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: a Systematic Review and Meta-Analysis
- The Cost Burden of Blood Cancer Care in Medicare a Longitudinal Analysis of Medicare Advantage and Fee for Service Patients Diagnosed with Blood Cancer
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- State and Specialty Pharmacy Drug Reimbursement Rates
- Breast Cancer (Recurrent Or Metastatic) Treatment Regimens
- Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer Christopher C
- North Carolina Division of Health Benefits Physician Administered Drug Program Catalog
- Oncology Agents Policy #: Rx.01.67
- Preclinical Activity of Abemaciclib Alone Or in Combination With
- Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
- Proton Pump Inhibitors and Oncologic Treatment Efficacy
- Abemaciclib (Interim Monograph)
- Oncology Proposal
- Protocol I3Y-MC-JPBX a Randomized Phase 2 Study
- Preclinical Activity of Abemaciclib Alone Or in Combination with Anti- Mitotic and Targeted Therapies in Breast Cancer
- Abemaciclib (Nsc# 783671)
- Items Supported by the CCF Medical Assistance Programmes
- Recommendations of the SEC (Oncology & Haematology)
- Corporate Connect: Kazia Therapeutics
- PD-1/PD-L1 Blockade Combination Approaches in Metastatic Breast Cancer
- Molecular Docking and Machine Learning Analysis of Abemaciclib In
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Standard Oncology Criteria Policy Number: Pending
- Download Flash Card
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Lessons Learned from Using CDK 4/6 Inhibitors to Treat Metastatic Breast Cancer Jame Abraham, MD, FACP
- Oncology-Off-Label-12-2020.Pdf
- Chemotherapeutic and Biologic Drugs
- Study Protocol, Prior to Randomization for Stage 1, Approximately 6 to 12 Patients Were to Be Enrolled in the Safety Lead-In Part of the Study
- All ETCTN Trials
- UK Chemotherapy Board
- Comparative Efficacy of Palbociclib, Ribociclib and Abemaciclib for ER+ Metastatic Breast Cancer: an Adjusted Indirect Analysis of Randomized Controlled Trials
- November 2020
- VERZENIO® (Abemaciclib) Tablets, for Oral Use Symptoms Or Radiological Changes Indicative of ILD/Pneumonitis
- Managing Pharmacotherapy in People Living with HIV And
- Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung Walter Z
- ERX.SPA.231 Abemaciclib (Verzenio)
- Helping Specialty Practices Increase Patient Access to Clinical Research Opportunities NOW AVAILABLE